UiPath launches a pro bono automation project with the Mater Hospital to free up nurses dealing with infection control including Covid-19
26.3.2020 15:00:00 EET | Business Wire | Press release
Today UiPath is launching a pro bono automation project with the Mater Misericordiae University Hospital. The initiative will see software robots assigned to the Infection Prevention and Control (IPC) Department at the Mater. This development will significantly reduce the administrative strain placed upon the department by multidrug resistant organisms or viruses such as Covid-19, enabling IPC nurses to spend more time with patients. The project will see the Mater offered free trial robot licenses for the IPC Department until the end of the year.
With data being automated through software robots, the information will be processed in a fraction of the current time, disseminating patient results in minutes. It will save the infection control department 3 hours per day, 18 hours per week and 936 hours a year which they can now spend managing the current Covid-19 pandemic.
As a result of Covid-19, the Mater expects to receive hundreds of swabs and microbiology tests in the coming months which the software robots can assist in rapid processing. The results can then be distributed to healthcare workers rapidly and essential infection prevention and control measures can be put into action.
Jincy Jerry, Assistant Director of Nursing, Infection Prevention and Control, MMUH, said: “Given that IPC nurses spend close to 30% of their day with administrative tasks, for the past few months I have been looking at ways to make software robots part of our daily jobs. With the COVID-19 pandemic unfolding now, it is crucial that all frontline staff are freed up as much as possible to spend time with patients and deal with this outbreak, rather than being in front of computers.”
“Not only will automation help with this, but it will also take the strain off the hospital as it continues to process huge amounts of more routine patient data in addition to Covid-19 specific information.”
“As we’ve already seen, alongside the public playing their part in physical distancing, fast diagnosis and appropriate self-isolation are crucial to preventing the spread of COVID-19. We’re confident that the project we’re embarking on will help mitigate the huge strain this outbreak is putting on healthcare organisations – not just in MMUH, but across Ireland.”
Mark O’Connor, Public Sector Director Ireland at UiPath, said: “Infection Prevention & Control is critical to help people stay healthy, and while COVID-19 is top of mind, this project will continue to deliver benefits long term. At this time of heightened stress and anxiety, it’s vital to free up doctors and nurses’ time for patients wherever it can be done.”
“Robotic process automation minimises, if not removes, the need for people to carry out repetitive, rules-based admin work – speeding up processes and ensuring they’re error-free. With a robot for every nurse approach, essential frontline staff will be freed to be nurses and not system administrators, being able to focus more on the quality of care – which can make a real difference when it comes to treating patients in times of need.”
O’Connor will be hosting a webinar on April 2, 2020 at 10 a.m. EST/3 p.m. BST to discuss Mater’s use of automation to respond to Covid-19-related scenarios. To register, visit this link.
For more information on UiPath, go to uipath.com.
About UiPath
UiPath is leading the era of “Automation First” by betting on a robot for each person and allowing robots to learn new skills through artificial intelligence (AI) and machine learning (ML). Through free and open training, UiPath brings digital era skills to millions of people around the world, improving business productivity and efficiency, employee engagement, and customer experience.
The company’s hyper-automation platform combines the number one Robotic Process Automation (RPA) solution with a full suite of capabilities, including process mining and analytics, that enable every organization to scale digital business operations at unprecedented speed. The company has already automated millions of repetitive, mind-numbing tasks for businesses and government organizations all over the world, including more than 50% of the Fortune 500 and 8 of the Fortune 10.
UiPath has recently been recognised as the top company in The Deloitte Technology Fast 500 for 2019, a ranking of the fastest growing public and private technology companies in North America, and number 3 in the 2019 Forbes Cloud 100.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200326005081/en/
Contact information
Toni Iafrate
UiPath
toni.iafrate@uipath.com
978-239-5499
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines’ Foundational Hematology Franchise Leads Next Era of B-Cell Cancer Innovation at EHA 202612.6.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from its foundational hematology franchise at the 2026 European Hematology Association (EHA) Congress in Stockholm. Updated results from tacabrutideg (BGB-16673), a potential best-in-class Bruton’s tyrosine kinase (BTK) degrader, demonstrated durable responses in pretreated relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), with early activity also seen in BTK inhibitor–naïve patients. These data are complemented by results from the all-oral combination of BRUKINSA® (zanubrutinib) plus next-generation BCL2 inhibitor BEQALZI™ (sonrotoclax; ZS), which continue to demonstrate rapid, deep, durable responses across multiple B-cell malignancies. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “BTK inhibition has reshaped the treatment of B-cell cancers, and we believe degradation is the next leap forwa
Cyviz: Microsoft’s Immersive Approach to Collaboration12.6.2026 10:00:00 EEST | Press release
Watch Video Case Study >> This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612831180/en/ Watch Video Case Study >> https://www.cyviz.com/case-studies/microsoft-immersive-suite/ As business and technology environments grow more complex, establishing shared understanding across disciplines has become critical. The Immersive Suite is designed for active collaboration, where visual narratives, data, and technical content are explored interactively. This allows participants to test scenarios, align perspectives, and move more efficiently from discussion to decision. “We deliberately work with familiar tools like PowerPoint. That allows us to focus on storytelling and interaction rather than explaining technology, making collaboration more natural and effective,” says Joris Haverkort, Chief Technology Officer for Microsoft Netherlands. A key principle is simplicity at scale. Instead of relying on specialized tools, users build co
LTM Launches AI 1000 to Develop the Next Generation of Forward Deployed Engineers12.6.2026 09:14:00 EEST | Press release
LTM, the Business Creativity partner to the world’s largest enterprises, today announced AI 1000, a strategic workforce transformation initiative anchored by a dedicated Center of Excellence (CoE). The program will develop a pool of 1,000+ AI-certified engineers, including Forward Deployed Engineers (FDEs), to help enterprises adopt, deploy, and scale AI. The launch comes amid a major shift in enterprise tech talent. The FDE — among the fastest-growing roles in the AI ecosystem — combines the technical knowledge of LLMs and domain SLMs with business understanding to turn ideas into quantifiable ROI accretive outcomes and to drive client adoption. AI 1000 is LTM’s structured response to this shift: it provides the training, platforms, and governed career frameworks to develop FDEs at scale. AI 1000 takes an end-to-end approach to talent development via a four-stage model: Identify, Enable, Deploy, and Govern. It starts by identifying high-potential engineers using a proprietary AI Readi
NTT DATA Group Appoints Kazuhiko Nakayama as New President and Chief Executive Officer12.6.2026 09:00:00 EEST | Press release
NTT DATA Group, a global leader in AI, digital business and technology services, today announces that the Board of Directors has approved the appointment of Kazuhiko Nakayama as NTT DATA Group’s new President and Chief Executive Officer, effective June 12, 2026. Yutaka Sasaki, former President and CEO of NTT DATA Group, will assume the role of Senior Executive Vice President of NTT, Inc., effective June 18. Serving most recently as CFO of NTT DATA Group, Nakayama brings proven leadership and a depth of expertise and experience in defining business strategy and delivering growth. He will continue to strengthen the competitive advantages of the $30+ billion business whilst accelerating it’s AI-centered growth strategy across the 70+ countries and regions in which it operates. NTT DATA Group’s growth strategy will focus on two key areas alongside its core business operations: AI‑empowered New Value & Productivity; and Next‑Generation Infrastructure. It aims to lead in areas such as Operat
Venture Global Announces Closing of $2.25 Billion of Senior Secured Notes12.6.2026 00:00:00 EEST | Press release
Venture Global LNG, Inc. (“Venture Global”) announced today that its wholly-owned subsidiary, Venture Global LNG, Inc. (the “Issuer”) has closed its offering of $1.125 billion aggregate principal amount of its 6.375% senior secured notes due 2034 (the “2034 Notes”) and $1.125 billion aggregate principal amount of its 6.625% senior secured notes due 2036 (the “2036 Notes” and, together with the 2034 Notes, the “Notes”). The Issuer used the gross proceeds from the offering to redeem all of the Issuer’s outstanding 8.125% senior secured notes due 2028 (the “Existing 2028 Notes”) and used cash on hand to pay the redemption premium and related fees and expenses for the offering and the redemption. The 2034 Notes will mature on December 15, 2034, and the 2036 Notes will mature on June 15, 2036. The Notes were issued at par. The Notes will initially not be guaranteed by any of the Issuer’s subsidiaries. In the future, certain of the Issuer’s subsidiaries that incur or guarantee certain amount
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
